Phase I/II Study of the Combination of Irinotecan and POF (POFI) and Tislelizumab — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Phase I/II Study of the Combination of Irinotecan and POF (POFI) and Tislelizumab — Stella

Recruiting

Back to Gastric Cancer Stage IV trials

Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.

Trial locations(1 site)

China

Fujian cancer hospital, Fuzhou, Fujian

Key details

Phase

Early testing / Safety & dosing

Sponsor

Fujian Cancer Hospital

Enrollment target

~51 participants

Started

February 2023

Primary completion

October 2024

This trial's estimated completion date has passed — the record may not be fully up to date.

Age range

18 Years – 75 Years

Last updated February 2025

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.

View full record on ClinicalTrials.gov